


## CLAIMS

1. A compound of the structure



where A is -CO- or -CHOH- and R is CH<sub>3</sub> or H, and the stereochemically isomeric forms and diastereomers thereof, with the provisos that  
 A is not -CO- when R is CH<sub>3</sub>,  
 A is not -CO- when R is H if the compound is a racemate,  
 A is not -CHOH- when R is CH<sub>3</sub> if the compound is a racemate,  
 A is not -CHOH- when R is H if the compound is a racemate,  
 and pharmaceutically acceptable salts and solvates thereof.

2. A compound according to claim 1, where R is H and A is -CO- and the compound is of the R-configuration.
3. A compound according to claim 1, where R is H and A is -CO- and the compound is of the S-configuration.
4. A compound of claim 1, where R is Me and A is -CHOH- and where said stereochemically isomeric forms are selected from the group consisting of the R,R-, R,S-, S,R- and S,S-configurations.
5. The compounds of claim 1, where R is H and A is -CHOH- and where said stereochemically isomeric forms are selected from the group consisting of the R,R-, R,S-, S,R- and S,S-configurations.
6. A method for synthesis of the stereochemically active compounds according to claim 1, where R is H and A is -CO- and being of the R-

or S-configuration, comprising the conversion of the corresponding stereochemical isomers of ketotifen into their 1-(2,2,2-trichloroethoxycarbonyl) nor-intermediates, followed by Cd/Pb-catalyzed cleavage to the products.

7. A method for preventing or treating a disease selected from the group consisting of respiratory disorders, allergic disorders, dermal disorders, gastrointestinal disorders and ocular disorders, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of racemic norketotifen and stereochemical isomers thereof, stereochemical isomers of ketotifen, racemic 10-hydroxy-ketotifen and the R,R-, R,S-, S,R- and S,S-isomers thereof and racemic 10-hydroxy-norketotifen and the R,R-, R,S-, S,R- and S,S-isomers thereof, or pharmaceutically acceptable salts or solvates thereof, while avoiding the dose-limiting sedative side effects of ketotifen.
8. The method of claim 7, wherein said respiratory disorder is selected from the group consisting of chronic obstructive pulmonary disease (COPD), asthma, cough, bronchitis and bronchial hyperreactivity.
9. The method of claim 7, wherein said allergic disorder is selected from the group consisting of allergic rhinitis, urticaria, allergic conjunctivitis and allergic keratitis.
10. The method of claim 7, wherein said dermal disorder is selected from the group consisting of atopic dermatitis, urticaria other itching or inflammatory conditions and psoriasis.
11. The method of claim 7, wherein said gastro-intestinal disorder is selected from the group consisting of hypersecretory syndromes including the Zollinger-Ellison syndrome, gastric irritation, enteritis, gastric and duodenal ulcers, gastric reflux, acid indigestion, motility disorders, and heartburn.
12. The method of claim 7, wherein said ocular disorder is selected from the group consisting of conjunctivitis, keratitis, blepharitis, episcleritis, scleritis, uveitis, neuritis, arteritis and sympathetic ophthalmia.

13. The method of claim 7, wherein the therapeutically active compound or a pharmaceutically acceptable salt or solvate thereof is administered by inhalation or nasal insufflation or by parenteral, topical, dermal, transdermal, rectal, sublingual, conjunctival or oral administration.
14. The method according to claim 7, wherein the therapeutically active compound or a pharmaceutically acceptable salt or solvate thereof is administered orally.
15. The method according to claim 7, wherein the therapeutically active compound or a pharmaceutically acceptable salt or solvate thereof is administered orally in an extended release formulation.
16. The method according to claim 7, wherein the therapeutically active compound or a pharmaceutically acceptable salt or solvate thereof is administered topically.
17. The method according to claim 7, wherein the therapeutically active compound or a pharmaceutically acceptable salt or solvate thereof is administered transdermally.
18. The method of claim 7, wherein the amount of the therapeutically active compound is administered from about 0.5 mg to about 200 mg, one to four times per day.
19. The method of claim 7, wherein a solid, semi-solid, liquid, suspension, aerosol or topical or transdermal pharmaceutical composition, comprising a therapeutically effective amount of the therapeutically active compound, or a pharmaceutically acceptable salt or solvate thereof, is administered in combination with a pharmaceutically acceptable carrier or carrier system.
20. A method comprising administering to a mammal in need thereof a composition, said composition comprising a therapeutically active amount of racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-norketotifen or an optically active isomer of ketotifen or a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof together with one or more drugs of the class consisting of adrenergic antagonists, analgesics,

antihypertensive agents, calcium antagonists, antihistamines, anticholinergic agents, antibacterial agents, antiviral agents, anti-inflammatory agents, bronchodilators, decongestants, steroids, leucotriene antagonists, lipxygenase inhibitors, local anesthetics, vasoconstrictors, vasodilators, cough suppressants, and expectorants.

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

<

add  
A<sub>2</sub> separate  
page